Epizyme Inc (NASDAQ:EPZM)
| 4.96 Delayed Data As of Oct 15 |  0.00 / 0.00%Today’s Change | 4.72 Today|||52-Week Range 14.30 | -54.33% Year-to-Date |
Latest EPZM News | Press Releases
| Epizyme's (EPZM) Tazverik Aids Growth, Overdependence a Woe Oct 14 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 4.96 |
| Today’s open | 5.04 |
| Day’s range | 4.88 - 5.05 |
| Volume | 50,944 |
| Average volume (3 months) | 1,006,629 |
| Market cap | $507.2M |
Data as of 4:00pm ET, 10/15/2021
Growth & Valuation
| Earnings growth (last year) | -19.08% |
| Earnings growth (this year) | +5.30% |
| Earnings growth (next 5 years) | +38.00% |
| Revenue growth (last year) | -33.77% |
| P/E ratio | NM |
| Price/Sales | 69.56 |
| Price/Book | 3.39 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VSTMVerastem Inc | 0.00 | 0.00% |
| ANIPANI Pharmaceuticals ... | 0.00 | 0.00% |
| SELBSelecta Biosciences ... | 0.00 | 0.00% |
| ALDXAldeyra Therapeutics... | 0.00 | 0.00% |
Data as of 4:29pm ET, 10/15/2021
Financials
| Next reporting date | November 3, 2021 |
| EPS forecast (this quarter) | -$0.49 |
| Annual revenue (last year) | $15.8M |
| Annual profit (last year) | -$231.7M |
| Net profit margin | -1,469.95% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
